- Home
- EYPT
as of 12-12-2025 3:58pm EST
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 1.5B | IPO Year: | 2005 |
| Target Price: | $29.60 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.91 - $19.11 | Next Earning Date: | 11-05-2025 |
| Revenue: | $42,339,000 | Revenue Growth: | -7.38% |
| Revenue Growth (this year): | -25.03% | Revenue Growth (next year): | -66.40% |
AI-Powered EYPT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of EyePoint Pharmaceuticals Inc. (EYPT)
Director
Avg Cost/Share
$15.11
Shares
9,300
Total Value
$140,477.43
Owned After
206,547
SEC Form 4
Avg Cost/Share
$15.70
Shares
60,000
Total Value
$942,240.00
Owned After
8,265,000
SEC Form 4
Director
Avg Cost/Share
$14.95
Shares
500
Total Value
$7,475.00
Owned After
206,547
SEC Form 4
Director
Avg Cost/Share
$14.95
Shares
200
Total Value
$2,990.00
Owned After
206,547
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$11.61
Shares
2,722
Total Value
$31,602.42
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Lurker Nancy | EYPT | Director | Dec 4, 2025 | Sell | $15.11 | 9,300 | $140,477.43 | 206,547 | |
| Cormorant Asset Management, LP | EYPT | Other | Dec 4, 2025 | Sell | $15.70 | 60,000 | $942,240.00 | 8,265,000 | |
| Lurker Nancy | EYPT | Director | Nov 28, 2025 | Sell | $14.95 | 500 | $7,475.00 | 206,547 | |
| Lurker Nancy | EYPT | Director | Nov 26, 2025 | Sell | $14.95 | 200 | $2,990.00 | 206,547 | |
| Ribeiro Ramiro | EYPT | Chief Medical Officer | Nov 11, 2025 | Sell | $11.61 | 2,722 | $31,602.42 | 0 |
Compare EYPT vs Leading Stocks
See how EYPT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EYPT EyePoint Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.